[{"abstract": "Such a move would be aimed at putting pressure on the British drug maker, which has turned down a number of informal takeover approaches.", "web_url": "https://dealbook.nytimes.com/2014/04/27/pfizer-said-to-pursue-astrazeneca/", "snippet": "Such a move would be aimed at putting pressure on the British drug maker, which has turned down a number of informal takeover approaches.", "lead_paragraph": "Pfizer is close to publicly unveiling its interest in acquiring AstraZeneca of Britain, a person briefed on the matter said on Sunday, in what would be one of the biggest deals among drug makers.", "print_section": "B", "print_page": "4", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-articleLarge.jpg", "height": 440, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 440}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-jumbo.jpg", "height": 751, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-superJumbo.jpg", "height": 1501, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Move for AstraZeneca Seen", "kicker": "DealBook", "content_kicker": null, "print_headline": "Pfizer Move for AstraZeneca Seen", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}], "pub_date": "2014-04-28T02:37:44+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Michael J. de la Merced", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4d906e1d-ead1-5449-b57a-6b03727752a2", "word_count": 308, "uri": "nyt://article/4d906e1d-ead1-5449-b57a-6b03727752a2"}, {"abstract": "The Swedish drug maker rejected an increased takeover offer from the generic pharmaceutical company based in Canonsburg, Pa.", "web_url": "https://dealbook.nytimes.com/2014/04/28/meda-again-rejects-takeover-bid-by-mylan/", "snippet": "The Swedish drug maker rejected an increased takeover offer from the generic pharmaceutical company based in Canonsburg, Pa.", "lead_paragraph": "LONDON \u2014 The Swedish drug maker Meda said on Monday that it had rejected an increased takeover offer from the generic pharmaceutical company Mylan.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-meda/dbpix-meda-articleLarge.jpg", "height": 157, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/04/29/business/dbpix-meda/dbpix-meda-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 157}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-meda/dbpix-meda-jumbo.jpg", "height": 269, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-meda/dbpix-meda-superJumbo.jpg", "height": 537, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-meda/dbpix-meda-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/04/29/business/dbpix-meda/dbpix-meda-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-meda/dbpix-meda-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Meda Again Rejects Takeover Bid by Mylan", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "subject", "value": "Stocks and Bonds", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Meda AB", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Mylan Inc", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 7, "major": "N"}, {"name": "glocations", "value": "Pennsylvania", "rank": 8, "major": "N"}, {"name": "glocations", "value": "Stockholm (Sweden)", "rank": 9, "major": "N"}, {"name": "glocations", "value": "Sweden", "rank": 10, "major": "N"}], "pub_date": "2014-04-28T08:19:35+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chad Bray", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/7e7b871d-0b39-5086-9b4f-1e7ceb83c76c", "word_count": 328, "uri": "nyt://article/7e7b871d-0b39-5086-9b4f-1e7ceb83c76c"}, {"abstract": "France puts the brakes on General Electric\u2019s bid for Alstom. | Investors are looking for other ways to profit from the aftermath of the housing crisis. | Pfizer continues its pursuit of AstraZeneca. | Elizabeth Warren seeks a level playing field.", "web_url": "https://dealbook.nytimes.com/2014/04/28/morning-agenda-france-stalls-g-e-s-alstom-bid/", "snippet": "France puts the brakes on General Electric\u2019s bid for Alstom. | Investors are looking for other ways to profit from the aftermath of the housing crisis. | Pfizer continues its pursuit of AstraZeneca. | Elizabeth Warren seeks a level playing field.", "lead_paragraph": "The French government on Sunday sought to discourage General Electric\u2019s bid for Alstom, one of the largest industrial companies in France, warning that economic sovereignty was at stake, David Jolly writes in DealBook. G.E. is looking to buy Alstom\u2019s energy business, and France\u2019s economic minister had been scheduled to meet on Sunday with Jeffrey R. Immelt, the chief executive of G.E.", "source": "The New York Times", "multimedia": [], "headline": {"main": "France Stalls G.E.\u2019s Alstom Bid", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2014-04-28T12:05:49+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Sydney Ember", "person": [{"firstname": "Sydney", "middlename": null, "lastname": "Ember", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/7a5234a2-9d0b-5738-961a-15133ca018ba", "word_count": 1785, "uri": "nyt://article/7a5234a2-9d0b-5738-961a-15133ca018ba"}, {"abstract": "If the British drug company AstraZeneca cannot make Pfizer go away, it can certainly make it pay, Neil Unmack of Reuters Breakingviews contends.", "web_url": "https://dealbook.nytimes.com/2014/04/28/why-pfizer-needs-to-do-more-to-win-astrazeneca/", "snippet": "If the British drug company AstraZeneca cannot make Pfizer go away, it can certainly make it pay, Neil Unmack of Reuters Breakingviews contends.", "lead_paragraph": "Pfizer will need to pile on more pressure if it wants to buy AstraZeneca. Pfizer has confirmed that it made a $99 billion cash-and-stock approach in January for AstraZeneca, its British rival, and is now renewing its suit. AstraZeneca\u2019s chief executive, Pascal Soriot, may ultimately struggle to resist a takeover, but he ought to be able to extract a better proposal.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Why Pfizer Needs to Do More to Win AstraZeneca", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "persons", "value": "Soriot, Pascal", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}], "pub_date": "2014-04-28T16:36:03+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Neil Unmack", "person": [{"firstname": "Neil", "middlename": null, "lastname": "Unmack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/eab3f930-477d-5011-8cb8-5e5f305e5303", "word_count": 446, "uri": "nyt://article/eab3f930-477d-5011-8cb8-5e5f305e5303"}]